Personalized medicine for patients with MDR-TB.
The emergence of MDR-TB is a cause of great concern due to difficulties in patient management and poor treatment outcomes. Currently the duration of treatment and the choice of drugs for patients with MDR-TB are standardized in many countries. This might not be the best approach since the optimal therapy may depend on different pathogen- and host-related features. Combining the introduction of technological innovations such as whole bacillary genome sequencing for the identification of drug-resistance-associated mutations, therapeutic drug monitoring and host-directed therapies with an individualized approach to MDR-TB management will likely lead to more tolerable, shorter and more efficient treatment regimens and an increase in the quality of life of those affected by MDR-TB.
Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany Clinical Tuberculosis Center, German Center for Infection Research (DZIF), Borstel, Germany International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany.
Ioana D
ID
Olaru
Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany Clinical Tuberculosis Center, German Center for Infection Research (DZIF), Borstel, Germany International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany Department of Medicine, Karolinska Institute, Stockholm, Sweden Department of Internal Medicine, University of Namibia School of Medicine, Windhoek, Namibia clange@fz-borstel.de.
Christoph
C
Lange
Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany Clinical Tuberculosis Center, German Center for Infection Research (DZIF), Borstel, Germany International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany.
Jan
J
Heyckendorf
D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016903:Drug Monitoring; D006801:Humans; D009169:Mycobacterium tuberculosis; D057285:Precision Medicine / Q000379:methods*; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis / Q000188:drug therapy*
D000995:Antitubercular Agents